A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

Exclusion Criteria

• •Has SBP \<100 mm Hg or symptomatic hypotension.
• •Awaiting heart transplantation, is receiving continuous IV infusion of an inotrope, or has or anticipates receiving an implanted ventricular assist device.
• •Amyloidosis or sarcoidosis.
• •Primary valvular heart disease requiring surgical procedure or intervention or has undergone a valvular surgical procedure or intervention within 3 months before randomization.
• •Hypertrophic cardiomyopathy.
• •Acute myocarditis or Takotsubo cardiomyopathy.
• •History of heart transplant.
• •Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia.
• •Acute coronary syndrome, or undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 3 months before randomization.
• •History of symptomatic carotid stenosis, transient ischemic attack (TIA), or stroke within 3 months before randomization.
• •Malignancy or other noncardiac condition limiting life expectancy to \<3 years.
• •Requires continuous home oxygen for severe pulmonary disease.
• •Interstitial lung disease.
• •Discontinuation or dose modification of GDMT or vericiguat within 4 weeks before randomization.
• •Recent history (within the last year) of drug or alcohol abuse or dependence.